Multiple Myeloma Coverage from Every Angle

SOHO 2021: ICARIA-MM Update on Isatuximab-Based Therapy for Multiple Myeloma

By: Vanessa A. Carter, BS
Posted: Wednesday, September 15, 2021

Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, Boston, and colleagues presented an update from the phase III ICARIA-MM trial of the monoclonal antibody isatuximab plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma during the 2021 Society of Hematologic Oncology (SOHO) Annual Meeting (Abstract MM-130). Based on their most recent data, the triplet regimen has yielded an improvement in the time to next treatment and the time from randomization to disease progression on the first subsequent therapy or death (PFS2), compared with pomalidomide and dexamethasone alone. In addition, a “strong trend” in overall survival benefit was reported with the inclusion of isatuximab.

A total of 307 patients with relapsed and refractory multiple myeloma who received at least two prior therapies were recruited for this study. Participants were randomly assigned to receive pomalidomide and low-dose dexamethasone with (n = 154) or without (n = 153) isatuximab.

At the median follow-up of 35.3 months, 27 patients given isatuximab and 12 patients given pomalidomide and dexamethasone alone remained on treatment; 60% and 72% of patients received subsequent therapy, respectively. The median time to next treatment with isatuximab was significantly longer than without it (15.5 vs. 8.9 months; P < .0001), with a longer duration of therapy (47.6 vs. 24.0 weeks). Median PFS2 and overall survival appeared to be significantly improved with the isatuximab combination compared with pomalidomide and dexamethasone alone (17.5 vs. 12.9 months and 24.6 vs. 17.7 months).

Treatment-related adverse events affected 73% and 60% of participants receiving therapy with and without isatuximab, respectively. Of note, the most common events in patients given isatuximab were infusion reaction (38%), upper respiratory tract infection (34%), and diarrhea (30%), with grade 3 or 4 thrombocytopenia and neutropenia occurring more often in these individuals.

Disclosure: No disclosure information was provided.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.